Related Experiment Video
Updated: Aug 15, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Update on cancer vaccines
1Molecular Immunology Group, Cancer Sciences Division, Southampton University Hospitals Trust, UK. fs@soton.ac.uk
Purpose Of Review:
Vaccination against cancer has had a variable history, with claims of success often fading into disappointment. The reasons for this include poor vaccine design, inadequate understanding of the nature of the immune response, and a lack of objective measures to evaluate performance. The impact of genetic technology has changed everything. We now have multiple strategies to identify candidate tumor antigens, and we understand more about activation and regulation of immunity against cancer. There are novel vaccine strategies to activate specific attack on tumor cells. We also have modern assays using surrogate markers of performance to correlate with clinical effects. It is timely to select significant relevant papers to illustrate the growing potential for patients with cancer.
Recent Findings:
Recent findings include tumor antigen discovery and vaccine formulation, relevant knowledge concerning mechanisms of induction of effective immunity from preclinical models, and translation into clinical trials with objective evaluation of performance.
Summary:
The ability of the immune response to dispose of cancer cells is clear. Passive transfer of antibody or immune cells is already clinically successful. We are now in a position to harness new gene-based information to design vaccines capable of inducing effective and long-lasting immunity. Safe vaccines could be used either in patients or in transplant donors. Pilot clinical trials are the means of testing performance, with continuing vaccine design modification to target specific antigens in different cancers.
Insights
Cancer vaccines are evolving with genetic technology, offering new strategies to harness the immune system for effective, long-lasting cancer cell destruction. Clinical trials are key to refining these promising immunotherapies.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Cancer vaccination has a complex history marked by inconsistent results due to challenges in vaccine design and understanding immune responses.
- Advances in genetic technology have revolutionized cancer research, enabling new approaches to tumor antigen identification and immune system modulation.
Purpose of the Study:
- To review significant advancements in cancer vaccine development, highlighting the potential of novel strategies for patient treatment.
- To illustrate the growing potential of cancer vaccines informed by genetic technology and improved immunological understanding.
Main Methods:
- Review of recent findings in tumor antigen discovery and vaccine formulation.
- Analysis of preclinical models elucidating mechanisms of immunity induction against cancer.
- Evaluation of clinical trial data assessing vaccine performance using surrogate markers.
Main Results:
- Identification of novel tumor antigens and development of advanced vaccine formulations.
- Gained insights into the induction of effective anti-cancer immunity from preclinical studies.
- Successful translation of findings into clinical trials with objective performance evaluations.
Conclusions:
- The immune system's capacity to eliminate cancer cells is established, with passive immunotherapy already showing clinical success.
- Gene-based information now allows for the design of vaccines inducing potent, durable anti-cancer immunity.
- Pilot clinical trials are crucial for testing and refining vaccine designs targeting specific antigens across various cancers.
More Related Videos
Related Concept Videos
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...

